A Medicare Part D Squeeze Is Coming in 2027 as Premium Support Disappears
Nearly 25 million stand-alone drug-plan enrollees face a harsher financial landscape as premiums could rise, the standard deductible climbs to $700, and the annual out-of-pocket limit jumps to $2,400. For millions of older and disabled Americans, the next Medicare shock may arrive in an ordinary envelope this fall.
The Trump administration will end a temporary subsidy program that helped hold down premiums for stand-alone Medicare Part D prescription-drug plans. The assistance expires after December 31, 2026, leaving insurers to set 2027 premiums without the program’s additional financial support.
Medicare Part D is not disappearing. However, the protective layer that helped prevent large premium increases is being removed just as other prescription-drug costs are moving higher.
Washington is ending the help before households see the final bill.
The Part D Premium Stabilization Demonstration began in 2025 after the Inflation Reduction Act substantially redesigned Medicare’s prescription-drug benefit. The law created an annual limit on beneficiaries’ out-of-pocket drug spending. It also shifted a larger share of expensive prescription costs onto private insurance companies operating Part D plans.
Federal officials introduced the temporary demonstration because insurers warned that their increased financial responsibility could produce volatile premiums. The program gave participating stand-alone plans additional subsidies and limited how quickly their total premiums could rise.
In 2025, the demonstration included a uniform $15 reduction in the base beneficiary premium and a $35 limit on year-over-year monthly premium increases. For 2026, CMS reduced the uniform assistance to $10, increased the premium-growth limit to $50, and removed special risk-sharing protections. Now, the administration is eliminating the program entirely.
CMS said insurers have gained enough experience with the redesigned Part D benefit to calculate their 2027 costs without temporary assistance. The agency confirmed the decision in its 2027 bid announcement. CMS Administrator Dr. Mehmet Oz described the subsidy as a corporate “bailout.”
“We are stabilizing the market so this bailout is no longer needed,” Oz wrote on social media. He said premiums would increase by less than $10 for most affected Medicare recipients, while some would receive lower premiums.
That reassurance does not settle the matter. Final plan-level premiums will not become public until September, meaning beneficiaries have not yet seen the bills they will actually receive.
Nearly 25 million Part D enrollees enter a less protected market.
Approximately 24.9 million Medicare beneficiaries were enrolled in stand-alone Part D plans as of February 2026. These plans generally provide prescription coverage to people who receive their hospital and medical benefits through Original Medicare.
Another 31.3 million people received drug coverage through Medicare Advantage plans, according to KFF enrollment data. The distinction is crucial. The expiring demonstration applies to stand-alone prescription-drug plans. Medicare Advantage drug plans did not participate in it.
Medicare Advantage insurers can use federal rebate payments to reduce or eliminate the drug portion of their premiums. Stand-alone plans do not receive those same Medicare Advantage rebates, leaving them more exposed when temporary Part D support disappears.
In 2026, the average monthly premium for stand-alone plans was approximately $36. The average drug-coverage premium inside Medicare Advantage plans was about $8, with many Medicare Advantage members paying no separate drug premium. That imbalance could become more severe in 2027.
Higher stand-alone premiums could pressure some Original Medicare beneficiaries to consider Medicare Advantage. Yet a zero-dollar or low drug premium does not make the entire plan free. Medicare Advantage plans can have restricted provider networks, prior-authorization requirements and different out-of-pocket exposure for medical care.
For rural beneficiaries, the choice can become even more difficult. Some communities have fewer stand-alone drug plans, fewer Medicare Advantage options and longer travel distances to in-network providers or preferred pharmacies.
The 2027 Medicare numbers are moving in the wrong direction.
The expiring subsidy is only one part of the financial picture. CMS has also finalized a higher standard Part D deductible and a higher annual out-of-pocket threshold for 2027. These increases are separate from the administration’s decision to end the demonstration, but beneficiaries could experience them during the same year.
The national average monthly bid is not what beneficiaries pay. It represents the enrollment-weighted amount insurers estimate they will need to provide the basic Part D benefit. Medicare uses the bid when calculating payments to plans.
Still, its increase from $239.27 to $296.05 signals greater underlying cost pressure inside the program. The national base beneficiary premium will rise to $41.33. That figure is also not a universal monthly price. Each plan’s final premium can be higher or lower based on its bid, benefits, and geographic market.
The standard deductible will increase from $615 to $700. A beneficiary whose plan charges the full deductible could therefore pay $85 more before the plan begins sharing certain prescription costs. The annual out-of-pocket threshold will rise from $2,100 to $2,400, according to the official CMS rate announcement.
Beneficiaries with extremely high covered drug costs could pay $300 more before reaching the point where additional copayments and coinsurance stop. For someone whose premium increases by $20 per month and who reaches the annual spending threshold, those two changes alone could create up to $540 in additional yearly exposure. Actual costs will depend on the plan, prescriptions, and qualifying spending.
The 6% protection will not cap every person’s increase at 6%.
The Inflation Reduction Act limits annual growth in the national base beneficiary premium to 6% through 2029. That provision remains in place. However, it does not guarantee that every plan’s actual monthly premium will rise by no more than 6%.
A plan-specific premium also depends on the insurer’s bid compared with the national average, the value of any enhanced benefits, and expected prescription claims. Higher-income beneficiaries may pay an additional income-related Part D surcharge. We have already seen how widely premiums can move despite the national cap.
Some participating stand-alone plans were permitted to increase monthly premiums by as much as $50 in 2026 under the demonstration’s revised rules. The $41.33 base premium, therefore, should not be mistaken for the price every enrollee will pay. The decisive numbers will appear when CMS publishes its final 2027 plan landscape.
The end of the subsidy does not end other Medicare protections.
The Part D prescription benefit will continue in 2027. Medicare beneficiaries will still be able to purchase stand-alone plans or receive drug coverage through eligible Medicare Advantage plans. The annual out-of-pocket protection will also remain, although the threshold rises to $2,400.
After qualifying spending reaches that level, beneficiaries will owe no additional copayments or coinsurance for covered Part D drugs for the remainder of the year. The Extra Help program is not being eliminated. Extra Help is a separate benefit that assists qualifying people with limited income and resources with Part D premiums, deductibles, and prescription cost-sharing.
Ending the temporary demonstration also does not automatically change the price of every prescription. The immediate change concerns federal support used to restrain insurance premiums. Formularies, deductibles, drug tiers, copayments and pharmacy networks will still determine what people pay when filling prescriptions.
The danger lies in the combined effect. A beneficiary could receive a higher premium, face a larger deductible and discover that a medication has moved to a more expensive tier, all during the same enrollment year.
A low premium can hide a more expensive drug plan.
The cheapest monthly premium is not always the cheapest plan. One insurer may offer a low premium but charge the full $700 deductible. Another may charge more each month but provide better coverage for a beneficiary’s regular medications.
A plan can also place a drug on a higher formulary tier, switch from a fixed copayment to percentage-based coinsurance, or remove a local pharmacy from its preferred network. Any one of those changes can erase the apparent savings from a lower premium.
Among stand-alone Part D enrollees who paid a premium in 2026, the average was approximately $57 per month. Only a small share of stand-alone plan members had coverage with no drug deductible, according to KFF’s Part D analysis.
That makes automatic renewal increasingly risky. The familiar plan name may remain while its price, formulary, and pharmacy rules change underneath it.
The fall enrollment decision will carry greater financial consequences.
CMS expects to publish final premiums and plan availability in September. Medicare Open Enrollment runs from October 15 through December 7, with coverage changes taking effect January 1, 2027. Beneficiaries will need to examine more than the headline premium.
The most important comparison should include:
- The complete monthly premium
- Every regularly used prescription
- The plan’s formulary and drug tiers
- Copayments and percentage-based coinsurance
- The annual deductible
- Preferred and in-network pharmacies
- Prior-authorization requirements
- The estimated total annual cost
- Medical networks and prior authorization before choosing Medicare Advantage
Medicare’s official Plan Compare tool allows beneficiaries to enter prescriptions and pharmacies when estimating annual costs.
The administration argues that affordable plans will remain available. But availability does not guarantee that a low-cost plan will cover a person’s medications at an affordable price or include the pharmacy that person can reasonably reach.
For nearly 25 million stand-alone Part D enrollees, 2027 will bring fewer protections against premium increases, a higher standard deductible, and a larger out-of-pocket threshold. The program is not disappearing, but the cost of keeping coverage could become noticeably harder to absorb.
